Shanghai Fosun Pharmaceutical (600196.SH): The PD-L1 targeted antibody conjugate drug HLX43 has received approval for clinical trials.

17:00 31/07/2026

Fosun Pharma (600196.SH) announced that its controlling subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiaries (hereinafter collectively referred to as "Fuhong Hanlin"), have received approval from the National Medical Products Administration to conduct clinical trials for HLX43 (i.e., a PD-L1 targeted antibody conjugate) in combination with or without bevacizumab and chemotherapy for the treatment of advanced/metastatic solid tumors. Fuhong Hanlin plans to carry out relevant clinical research on this treatment regimen in China once conditions are met.

Shanghai Fosun Pharmaceutical (600196.SH) announced that recently, its controlling subsidiary Shanghai HENLIUS Biotechnology Co., Ltd. and its holding subsidiaries (hereinafter collectively referred to as HENLIUS) received approval from the National Medical Products Administration for conducting clinical trials of injectable HLX43 (a targeted PD-L1 antibody drug conjugate, hereinafter referred to as HLX43) in combination with or without bevacizumab chemotherapy for the treatment of advanced/metastatic solid tumors. HENLIUS plans to conduct relevant clinical research on this treatment scheme in China when conditions permit. The HLX43 involved in this treatment scheme is a targeted PD-L1 antibody drug conjugate (ADC) developed by HENLIUS through the conjugation of a newly licensed DNA topoisomerase I inhibitor small molecule toxin-peptide linker with its independently developed PD-L1 targeted antibody, intended for the treatment of advanced/metastatic solid tumors.

HK Stock Market Move | PV stocks continue to rise as the State Administration for Market Regulation conducts compliance guidance on pricing in the photovoltaic industry, and the standards for cost accounting are being accelerated for implementation.

HK Stock Market Move | IFBH (06603) fell over 11% as supply chain disruptions combined with weak demand, with net profit expected to drop by as much as 75% year-on-year in the first half of the year.

HK Stock Market Move | LEGEND HOLDING (03396) rose over 6% following a positive earnings forecast, expecting a net profit attributable to equity holders in the first half to increase by no less than 186% year-on-year.

HK Stock Market Move | IFBH (06603) fell over 11% as supply chain disruptions combined with weak demand, with net profit expected to drop by as much as 75% year-on-year in the first half of the year.